Bleeding in the Patient With a Malignancy: Is It an Acquired Factor VIII Inhibitor?

Many different factors can account for hemorrhagic complications in patients with malignancies. Potential etiologies include disease- or treatment-related impairment of bone marrow function, or trauma to highly friable and vascularized malignant tissues. Immune impairment may also occur in solid or...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2012-01, Vol.118 (2), p.312-320
Main Author: ESCOBAR, Miguel A
Format: Article
Language:English
Subjects:
Autoantibodies - blood
Biological and medical sciences
Disseminated Intravascular Coagulation - chemically induced
Factor VIII - antagonists & inhibitors
Factor VIII - immunology
Hemorrhage - etiology
Hemorrhage - therapy
Hemostatic Techniques
Humans
Immunosuppression
Medical sciences
Neoplasms - complications
Neoplasms - immunology
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many different factors can account for hemorrhagic complications in patients with malignancies. Potential etiologies include disease- or treatment-related impairment of bone marrow function, or trauma to highly friable and vascularized malignant tissues. Immune impairment may also occur in solid or hematologic malignancies, leading to spontaneous formation of inhibitory antibodies against coagulation factor VIII (FVIII). Because hemorrhage due to acquired FVIII inhibitors will not respond to conventional treatment algorithms for bleeding, failure to promptly recognize and diagnose this condition may result in undue morbidity and mortality. The persistence of FVIII autoantibodies in the patient with cancer may further complicate necessary invasive diagnostic or therapeutic procedures in the short term and lead to lethal bleeding in the long term. Oncologists must therefore maintain a high index of suspicion for this diagnosis as 1 of many potential causes of bleeding in patients with a malignancy.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.26304